Kudos to the authors for publishing this for sarcoma patients and sarcoma oncologists. Again points to challenges of conducting trials in this heterogeneous group. Interesting ASPS and EMC results.

This really has been the year for lymphoma! Check out this morning's press release re: ECHELON-1, with a significant OS benefit demonstrated with BV-AVD compared to ABVD. #lymsm streetinsider.com/dr/news.php?id…

High-risk #sarcoma patients treated with AI performed better than predicted, and this adds to the evidence for the efficacy of neoadjuvant AI in STS. ⁦Sandro Pasquali⁩ ⁦Alessandro Gronchi⁩ acsjournals.onlinelibrary.wiley.com/doi/ftr/10.100…

Excited to share our phase I/II of tisagenlecleucel in PCNSL: The Leukemia & Lymphoma Society ASH Mass General Cancer Center - Median # of prior therapies = 4 - ORR 58.3% (7/12) - CR rate 50% (6/12) - Responses seen beyond 12 months - Trafficking to CNS by flow and VCN ashpublications.org/blood/article/…

Last chance to have your say about how you approach DLBCL in our post-#ASH21 survey of lymphoma clinicians: redcap.uchicago.edu/surveys/?s=4ET… Closing this weekend - please RT Lymphoma Hub Jason Westin, MD FACP FASCO Ajay Major, MD, MBA Judith Trotman Lymphoma Research Foundation @lysalymphoma Krish Patel Pallawi Torka #lymsm

#ASCODailyNews Podcast: @JSweetenhamMD of UTSW Simmons Cancer Center & Dr. Sandra Kurtin of University of Arizona Cancer Center and president of APSHO discuss utilizing #AdvancedPracticeProviders to their full scope in #oncology 🎧 fal.cn/3mjDS

Delighted to announce the publication of BSH - Haematology guidelines on the frontline treatment of classical Hodgkin lymphoma. Great team of authors led by Dr George Follows. Sally Barrington David Cutter Pam McKay Eve Gallop-Evans Wendy & others! onlinelibrary.wiley.com/doi/10.1111/bj…

I always said Tucson is a special place 🥰!! PS - we are recruiting for Breast, Melanoma, Phase 1, Heme, and more University of Arizona COM - Division of Heme/Onc!! Message me for details! University of Arizona Cancer Center nytimes.com/interactive/20… @drhusnain01 Abhijeet Kumar Aaron J. Scott MD @akshay_982 Junaid Arshad Joann Sweasy University of Arizona Health Sciences

Wonderful discussion by Dr. Aaron Scott University of Arizona Cancer Center on early onset colorectal cancer ASCO today!

Steve Bialick, DO #TumorBoardTuesday Jon Trent, MD, PhD @seppobauer Junaid Arshad Mike Pishvaian Johnathan Ebben MD, PhD Brian Van Tine Sarcoma Foundation of America Therese - Hematology and Oncology Palma Dileo Brian Pico, MD Alessandro Gronchi Anette Duensing Tom Wei-Wu Chen Michael Wagner Christina Roland, MD, MS Maurício Ribeiro, MD Ankit Mangla, MD SARCOMA CONNECT Dario Callegaro gistchile Nadia Hindi Nam Bui Emily Keung, MD Chiara Fabroni Winan van Houdt Celso Mello Priscila Barreto Coelho, MD Solange Sierra Aimee Crago, M.D. Piotr Rutkowski Lara Davis Nathan Seligson Andrea Franza, MD Lady Sarcoma sylvie bonvalot Camila Martin Patrick Schöffski Chandrajit Raut Sydney Stern, PhD, MS Irenecg Fina cruz Elizabeth Davis Colectivo Gist España Dr JMartín-Broto Angela Lamarca Sarcoma Alliance The Life Raft Group CTOS July is sarcoma awareness month!!! "they" say it's rare but I disagree!! there are more sarcoma patients out there then reported. let's spread the word!!

#lymsm Ever wondered about the impact of M protein in your patients with MZL? Read our new paper spearheaded by Narendranath Epperla, MD, MS, FACP The James and Adam Olszewski MD, out now in Blood Advances ASH ashpublications.org/bloodadvances/…

Thank you ⁦University of Arizona Health Sciences⁩ for this kind write up! ⁦University of Arizona Cancer Center⁩ ⁦UA College of Medicine – Tucson⁩ Shroff named ASCO Woman Disruptor of the Year | UArizona Health Sciences healthsciences.arizona.edu/connect/honors…

Meet UArizona Cancer Center member Aaron Scott, MD, an academic medical oncologist extraordinaire––a caring, fifth generation Tucsonan making a difference for his patients and for all. bit.ly/4dgIaCN #BearDownonCancer

#ASCO24 #Sarcoma is on, with a review of immunotherapy in sarcoma Sandra P D'Angelo, MD Great review of data thus far and looking beyond -> we need to look at specific histologies and develop biomarkers for specific histologies

🎥Was great speaking with Tycel Phillips (Tycel Phillips) of City of Hope on glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) #MantleCellLymphoma Watch this space for the full interview👉VJHemonc.com ASCO #ASCO24 #HemOnc

Hey #ASCO24: We have life saving drugs and life threatening shortages. It’s time for solutions - sign our letter to demand action now. ASCO

David Kirsch, MD, PhD just changed SOC for UPS at #ASCO24, a #SARC viral SARC32 go.l pembro

initial data from SUC-SARC032 trial presented by David Kirsch, MD, PhD radiotherapy & surgery +/- pembrolizumab in patients with resectable stage III #sarcoma (UPS or LPS) 🔷2yr DFS 53% vs 70% 🔷no statistically significant difference in LRFS & DDFS 🔷OS data immature #ASCO24

Insurance companies aren't even trying to justify their coverage denials any more I didn't white anything out, there's just ... no reason

Important data in #richters field Excellent agent to combine in RT trials What is the combination strategy moving forward? #lymsm #CLL #pirtobrutinib #BRUIN